Opening Plenary: The Future of Cell & Gene Therapy | ATW 2025
Where is cell & gene therapy headed? This must-watch session kicks off ATW 2025 with key insights into innovation, investment, and diversity shaping the industry’s future.
💡 Key Takeaways:
🔹 Top 10 of Cell & Gene Therapy in 2025 – A deep dive into the biggest trends and breakthroughs
👩🔬 Advocating for Female Founders – Why investing in women leaders is critical for innovation
💡 Pioneering Hope in CGT – Exploring new approaches that will define the next decade
🔎 Panel discussion with industry leaders
Speakers:
🔹 Sarah Creviston – VP, Patient Advocacy & Public Affairs, Novartis Gene Therapies
🔹 Susan B. Nichols – CEO, Propel Biosciences
🔹 Becky Johnson-Kent – Head of Women in Advanced Therapies, Phacilitate
🔹 Lynn Fischer – CEO, KMAK Capital
🔹 Ryan Leahy – VP of Research, Phacilitate
🔹 Terry Pirovalakis – CEO, Elpida Therapeutics
🔹 Katherine High – Visiting Professor, Rockefeller University
🔹 Ignacio Nunez – COO, CellReady
🔹 Boro Dropulic – Executive Director, Caring Cross
🎟️ Stay ahead of the curve—join us at ATW 2026!
🔹 Pre-register now → https://ow.ly/5Ssp50Vaotw
📖 Download the ATW 2025 Show Brochure → https://ow.ly/raF450Vaouz
#ATW26 #CGT #CellTherapy #GeneTherapy #FutureOfBiotech #WomenInBiotech #Investment #BiotechInnovation